
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health is demonstrating a strong financial performance, with 4Q23 revenue reaching $96.8 million, surpassing both previous estimates and expectations from analysts. The company has shown a significant improvement in its average selling price (ASP) for systems, which increased approximately 20% quarter-over-quarter to $28.8K, reflecting a favorable shift in sales channels towards direct sales. Additionally, the positive revenue trends were primarily driven by strong consumer demand for consumables, indicating robust market traction for the company's product offerings.
Bears say
Beauty Health Co. has experienced a significant decline in new core delivery system placements, reporting 1,210 placements, which is over a 30% decrease both year-over-year and quarter-over-quarter, falling short of previous estimates. This deceleration is concerning, as new system placements are crucial for driving future consumables sales, which are integral to the company's profitability goals for 2024. Additionally, management's guidance for 1Q24 sales of $80 million and adjusted EBITDA of -$7.5 million is significantly below prior estimates, indicating potential challenges in achieving the projected full-year EBITDA target of over $40 million.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares